The role of prostaglandin E2 (PGE2) 
Introduction
Mononuclear phagocytes (M+)' exert a number of regulatory influences on lymphocyte function. Not only are MO or their whereby MO regulate immune responses is by producing arachidonic acid metabolites such as prostaglandin E2 (PGE2) (13-16). PGE2 has been shown to inhibit T cell proliferation (17, 18) and the production of lymphokines such as interleukin-2 (IL-2) and y-interferon (19) (20) (21) . In addition, PGE2 can have variable effects on the function of various suppressor T cell populations. Thus, in humans, PGE2 has been shown to facilitate the activity of the suppressor T cells that inhibit IL-2 production (19) while inhibiting the suppressive capability of those that regulate immunoglobulin production (22, 23) .
A number of aspects of B cell function have also been shown to be inhibited by PGE2. The generation of B cell colonies from murine spleen and lymph node (24) , as well as protein A-and phytohemagglutinin-stimulated growth of B cell colonies from human peripheral blood have been shown to be inhibited by PGE2 (25, 26) . In addition, we have recently found that Staphylococcus aureus (SA)-but not pokeweed mitogen (PWM)-stimulated human B cell proliferation is significantly inhibited by physiologic concentrations of PGE2 (27) .
In contrast to the inhibitory action of PGE2 on B cell proliferation, its effects on antibody formation have been less clearly defined. In vivo studies in mice showing that antibody responses could be significantly enhanced by cyclooxygenase inhibitors suggested a role for prostaglandins in regulating the generation of immunoglobulin-secreting cells (ISC) (28) . In addition, in vivo studies in man indicate that administration of cyclooxygenase inhibitors may augment secondary responses to immunization with viral antigens while having no effect on primary responses (29) . However, in vitro studies have not clearly defined a role for prostaglandins in the regulation of B cell responsiveness. For example, a number of disparate effects of PGE2 on PWM-stimulated immunoglobulin (Ig) production have been reported. Thus, inhibition of cyclooxygenase activity with indomethacin was found to have no effect on PWMinduced Ig secretion, whereas large concentrations of PGE2 (>l0-7 M) were reported to be inhibitory (22, 30) . By contrast, it has been shown that indomethacin may inhibit PWMstimulated Ig secretion and that low concentrations (-10-1 M) of PGE2 could reverse this inhibition (23) . These latter results have been interpreted as indicating that PGE2 can inhibit the function of a suppressor T cell involved in the regulation of Ig production, but that B cell function is not directly effected by these low concentrations of prostaglandin.
Larger concentrations of PGE2 (>3 X l0-' M) did appear to have a negative effect on B cell function in these studies. Thus, it appears that physiologic concentrations of PGE2 (-10-8 M; 22, 23, 29, 31) have little direct effect on B cell responsiveness although the regulatory action of suppressor T cells may be inhibited under some circumstances.
The studies described in this communication represent a continuation of experiments undertaken to examine in greater detail the effect of PGE2 on a number of aspects of human B cell responsiveness. Initially, we found that PGE2 directly inhibited B cell DNA synthesis and growth stimulated by SA but had a negligible effect on the production of B cell growth factor from mitogen-stimulated T cells (27) . In the studies reported in this communication, the effect of PGE2 on the generation of ISC from human peripheral blood B cells was examined. The results indicate that PGE2 exerts a number of specific inhibitory influences on the cells involved in antibody formation in man. Thus, PGE2 directly inhibited the generation of Ig-secreting cells from B cells stimulated with SA and T cell supernatants and also inhibited the capacity of T cells to secrete a factor(s) that supported B cell differentiation. These results indicate that PGE2 produced by MO, and possibly other cells, may have a profound effect on antibody production in humans.
Methods
Cell preparation. Peripheral blood mononuclear cells (PBM) were obtained from healthy adult volunteers by centrifugation of heparinized venous blood on sodium diatrizoate/Ficoll gradients (Isolymph; GallardSchlesinger Chemical Manufacturing Corp., Carle Place, NY). Cells were washed three times in Hanks' balanced salt solution (HBSS) before further processing.
Culture medium. All cultures were carried out in medium RPMI 1640 (Inland Laboratories, Austin, TX), supplemented with penicillin G (200 U/ml), gentamicin (10 Ag/ml), L-glutamine (0.3 mg/ml), and 10% fetal bovine serum (FBS; Microbiological Associates Inc., Bethesda, MD).
Cell separation. Cell populations were prepared as previously described (5) . PBM were separated into adherent cells and nonadherent cells by incubation on glass petri dishes for 1 h at 370C. The adherent cell population, which contained 85-90% MO by esterase staining, was treated with 40 ug/ml mitomycin C (Sigma Chemical Company, St. Louis, MO) for 45 min at 370C and washed three to four times before use. In some experiments, PBM were treated with L-leucine methyl ester (LME) as previously described (32) number of ISC found, which became more pronounced as the length of the culture was increased.
The effect of PGE2 in cultures stimulated by SA and T cell supernatant was markedly different. PGE2 did not alter the number of ISC detected after a 3-d incubation, independent of its time of addition. As the culture was prolonged, however, PGE2 became progressively more inhibitory. The One possible explanation for these results was that PGE2 interfered with the synthesis and/or secretion of Ig as has previously been suggested in the murine system (41) . However, the results shown in Table V These results suggested that SA that contained protein A augmented the degree of inhibition caused by PGE2. In order to confirm that conclusion, one additional experiment was carried out. B cells were stimulated for 48 h in the presence of SA, washed, cultured with T cell supernatant for an additional 3 d, and then assayed for the number of ISC. In the experiment shown in Fig. 2 , the addition of various concentrations of PGE2 during the terminal 72-h incubation with T cell supernatant caused dose-dependent inhibition of responsiveness. The addition of low concentrations of SA to these cultures markedly increased the degree of inhibition caused by all concentrations of PGE2. In the presence of SA, a comparable degree of inhibition was observed with 10-100-fold less PGE2 . These results support the conclusion that SA increases the sensitivity of activated B cells to the inhibitory action of PGE2. B cells obtained from LME-treated PBM were incubated for 48 h with SA in 17 X 100-mm polypropylene tubes, washed extensively, cultured in microwells with T cell supernatant, and assayed for the number of ISC after an additional 72-h incubation. In addition, the latter cultures contained various concentrations of PGE2 with or without additional SA (1:45,000 vol/vol). Numbers in parentheses indicate the PGE2-mediated percentage change in the number of ISC generated compared with the response noted without PGE2 (ethanol control).
Discussion
The experiments described herein were undertaken to examine the regulatory role of PGE2 on the generation of ISC from human peripheral blood B cells. This line of investigation was stimulated by the observation that a portion of MO One mechanism whereby MO and PGE2 altered the generation of ISC was by inhibiting the production of BCDF from mitogen-stimulated T cells. It should be noted that this inhibition was selective in that PGE2 had no effect on mitogeninduced production of B cell growth factor (BCGF) as asayed by the capacity of the supernatants to augment proliferation of SA-stimulated B cells. Thus, the supernatants of mitogenstimulated T cells cultured in the presence of PGE2, which were markedly deficient in BCDF activity as shown in the current study, were found to have comparable levels of BCGF activity as supernatants of control T cells (27) . Although PGE2 had little effect on the production of BCGF, it has been shown to inhibit secretion of a variety of other T cell lymphokines, including IL-2 (19, 20) , 'y-interferon (21) , and leukocyte migration inhibitory factor (44 (48) . Additional confirmation of the potential complexity of the effect of PGE2 on B cell function is the finding that further differentiation of murine B cells as detected by the expression of a surface plasma cell antigen appears to be inhibited by inducers of cAMP (49) . The differing sensitivities of various stages of B cell activation to modulation by PGE or changes in cAMP is emphasized by the finding that PGE1 or dibutyryl cAMP enhanced antibody production by primed rabbit B cells when added at the initiation of culture, but decreased antibody production when added >24 h later (50) . Thus, the various effects of PGE2 observed on the differentiation of human B cells in response to T cell supernatants or SA and T cell supernatants may reflect differences in the stages of maturation of the respective B cell precursors.
The mechanism of PGE2-mediated inhibition of the generation of ISC from SA-and BCDF-stimulated B cells has not been clearly delineated. It is important to note, however, that PGE2 did not need to be present from the initiation of culture to cause inhibition. Thus, PGE2 could be added at any time during the culture and cause inhibition of the number of ISC observed within 24 h of subsequent culture. Indeed, the initial ISC generated and observed within 3 d of the start of culture appeared to be resistant to the effects of PGE2. Two features of this system are useful in interpreting these results. First, the ISC generated between days 3 and 7 of culture are not stable terminally differentiated plasma cells, but rather rapidly dividing Ig-secreting lymphoblasts (51) . In addition, PGE2 has been shown to cause significant inhibition of proliferation of B cells stimulated by SA plus BCGF-containing T cell supernatants although it has no effect on initial activation (27) . In this system, inhibition of B cell proliferation was noted even when PGE2 was added to culture after initial B cell division. These results suggest the possibility that the mechanism of action of PGE2 may involve inhibition of growth of SA-activated and rapidly proliferating ISC. Thus, PGE2 produced at inflammatory sites may play an important role in regulating on-going antibody responses.
Previous reports have suggested that one additional action of PGE2 is to inhibit the regulatory influence of suppressor T cells (22), although this has not been uniformly found. Thus, in different systems it has been claimed that PGE2 can either inhibit suppressor T cell function (52) or stimulate suppressor T cells that limit IL-2 production (43), antibody formation induced by trinitrophenyl-Ficoll in cultures of cells from elderly subjects (53), or concanavalin A-induced suppressors with nonspecific inhibitory effects (54) . In the experiments reported here, effects of PGE2 on suppressor cell function were not examined in detail. Although it was possible that the induction of suppressor cells explained the limitation of BCDF production caused by PGE2, a contrasuppressive effect of PGE2 was not routinely observed. However, it is clear that in other systems an inhibitory effect on suppressor cell function may also be an important immunomodulatory effect of PGE2 on antibody formation (22, 55) .
As a result of in vitro studies, it has become apparent that the effect of PGE2 on antibody responses may be complex, determined by the interplay of a number of distinct, often opposing physiologic processes. The relationship of these various influences may contribute to the disparate influence of inhibitors of cyclooxygenase activity observed on various specific antibody responses in intact animals or humans. Thus, inhibitors of prostaglandin biosynthesis may augment the antibody response to sheep erythrocytes in mice (28) . In humans, however, inhibitors of cyclooxygenase activity do not uniformly cause an increase in all antibody levels. Administration of these agents has, for example, been reported to augment secondary antibody responses to viral antigens while having no effect on primary responses (29) . During various pathologic conditions, the relationship between the regulatory mechanisms controlling the magnitude of antibody responses may be altered and thus lead to differential effects of locally produced PGE2. For example, the local production of large concentrations of PGE2 by rheumatoid synovium (56, 57) has been suggested to lead to tonic inhibition of suppressor T cell function (22) with resultant local production of Ig and rheumatoid factor. In this circumstance, administration of cyclooxygenase inhibitors decreases titers of circulating rheumatoid factor, apparently by a permissive effect on suppressor T cell activity (58) . Thus, PGE2 may augment or inhibit antibody production in humans depending on the nature of the response, the regulatory influences involved in its control, and the derangements in control mechanisms caused by various pathologic influences.
In summary, MO-derived PGE2 at physiologically relevant concentrations has been shown to exert a number of inhibitory influences on the generation of ISC in humans. PGE2 inhibited the production of BCDF from mitogen-stimulated T cells and suppressed the generation of ISC induced by SA-and BCDFcontaining T cell supernatants. These results support the conclusion that PGE2 may play an important role in regulating the magnitude of antibody responses in vivo.
